
CLAIMS

What is claimed is:

1. A compound of Formula (I):



Formula I

wherein:

X is CH or N;

R^1 is selected from H, halo, CN, C_1-C_{10} alkyl or halo(C_1-C_4)alkyl, wherein C_1-C_{10} alkyl, or halo(C_1-C_4)alkyl is optionally substituted;

R^2 is aryl, cycloalkyl, arylalkyl, or heterocyclyl, wherein the aryl, cycloalkyl, arylalkyl, or heterocyclyl is optionally and independently substituted at one or more carbon atoms with 1-4 R^5 or R^{5a} groups; and wherein aryl and heterocyclyl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with 1-4 R^6 or R^{6a} groups;

R^3 is independently halo, CN, or R^7; and

R^4 is selected from $(CH_2)_nOH$, $(CH_2)_nNR^{11}R^{12}$, $C(O)NHR^7$, $C(O)NR^{11}R^{12}$, $C(O)OR^7$, $C(O)R^7$, $C(O)NR^7R^7$, $C(O)NR^7R^8$, $(CH_2)_nNR^7R^7$, $(CH_2)_nNR^7R^8$, $(CH_2)_nCN$, $(CH_2)_nSR^7$, $(CH_2)_nS(O)_nR^7$, or $(CH_2)_nS(O)_nNR^7R^7$, wherein each n is independently 1 or 2;

wherein:

Each R^5 is independently selected from halo, CF_3, SR^7, OR^7, $OC(O)R^7$, $O(CH_2)_nNR^7R^7$, $O(CH_2)_nNR^{11}R^{12}$, $O(CH_2)_nR^7$, $O(CH_2)_nC(O)NR^{11}R^{12}$, $O(CH_2)_nC(O)NR^7R^7$, NR^7R^7, NR^7R^8, $NHC(O)NH_2$, $C(O)OR^7$, NO_2, CN, $C(O)R^7$, OSO_2CH_3, $S(O)_nR^7$, $S(O)_nNR^7R^7$, $NR^7C(O)NR^7R^7$, $NR^7C(O)R^7$, $NR^7C(O)OR^7$, $NR^7S(O)_nR^7$, or $NR^{11}R^{12}$, wherein each n is independently 1 or 2;

Each R^{5a} is independently selected from amino, halo, hydroxy, C_1-C_{10} alkyl, C_2-C_{10}alkenyl, C_3-C_{10} alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{10}cycloalkenyl, alkoxy, haloalkyl, aryl, heteroaryl, or heterocyclyl, wherein the C_1-C_{10} alkyl, C_2-C_{10}alkenyl, C_3-C_{10} alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{10}cycloalkenyl, alkoxy, haloalkyl, aryl, heteroaryl, or heterocyclyl is optionally and independently substituted with 1 to 3 groups selected from halo, hydroxy, alkyl, R^9, or R^{10};

Each R^6 is independently R^7, $C(O)CH_2CN$, $C(O)R^7$, $C(O)OR^7$, $CO_2(C_1$-C_6alkyl), $C(O)NR^7R^7$, $SO_2NR^7R^7$,or SO_2R^7;

Each R^{6a} is independently hydroxy, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{10} cycloalkenyl, haloalkyl, wherein each R^{6a} group is optionally and independently substituted with 1-3 groups selected from hydroxy, aryl, alkyl, halo, R^9, or R^{10};

Each R^7 is independently H, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12}cycloalkenyl, aryl, aryl(C_1-C_4)alkyl, haloalkyl, heteroaryl, or heterocyclyl, wherein the C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12}cycloalkenyl, aryl, aryl(C_1-C_4)alkyl, haloalkyl, heteroaryl, or heterocyclyl is optionally and independently substituted with 1-4 groups selected from aryl, cycloalkyl, heteroaryl, heterocyclyl, alkyl, halo, amino, hydroxy, R^9, or R^{10};

Each R^8 is independently $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^7$, or $S(O)_nR^7$, wherein n is 1 or 2;

Each R^9 is independently CF_3, SR^7, OR^7, NR^7R^7, $NR^{11}R^{12}$, $C(O)NR^7R^7$, $C(O)NR^{11}R^{12}$, $S(O)_nNR^7R^7$, or $S(O)_nR^7$, wherein each n is independently 1 or 2;

Each R^{10} is $C(O)O(C_1\text{-}C_6)$alkyl, or halo$(C_1\text{-}C_4)$alkyl; and

R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form:

i) a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered saturated or partially saturated ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

ii) a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

iii) a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom is optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

iv) a 9-10 membered saturated or partially saturated bicyclic ring having 1-5 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfoxide, sulfone, carboxamide or sulfoxamide; or

v) a 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1, wherein R^2 is an aryl selected from: a 5-6 membered monocyclic aryl group having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-10 membered bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone; an 8-10 membered partially saturated bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone; or an 8-10 membered partially saturated bicyclic aryl group having a carboxamide or sulfoxamide.

3. The compound of Claim 2, wherein R^2 is a 5-6 membered monocyclic aryl having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally and independently substituted with 1-4 R^5 or R^{5a} groups.

4. The compound of Claim 3, wherein the 5-6 membered monocyclic aryl is phenyl or pyrimidinyl optionally and independently substituted with 1, 2, or

3 groups selected from methyl, ethyl, phenyl, isopropyl, methoxy, hydroxyethoxy, CF_3, OC_6H_5, $OCH_2CH_2NR^{11}R^{12}$, $OCH_2CH_2NR^7R^7$, $OCH_2C_6H_5$, $OCH_2C(O)NR^{11}R^{12}$, $OCH_2C(O)NR^7R^7$, OSO_2CH_3, SO_2CH_3, SO_2NHCH_3, or $NR^{11}R^{12}$.

5. The compound of Claim 2, wherein R^2 is an 8-10 membered bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone, wherein the 8-10 membered bicyclic aryl group is selected from indolyl, indazolyl, benzothiophenyl, benzothiazolyl, benzofuranyl, naphthyl, or quinolinyl optionally and independently substituted with 1, 2, or 3 groups selected from alkyl, aryl, heteroaryl, alkoxy, halo, CF_3, OCF_3, or SO_2CH_3 at the substitutable carbon atoms or nitrogen atom, wherein alkyl, aryl, or heteroaryl is optionally substituted with hydroxy, amino, or sulfone.

6. The compound of Claim 2, wherein R^2 is an 8-10 membered partially saturated bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone, wherein the 8-10 membered partially saturated bicyclic aryl group has a phenyl ring fused to a non-aromatic carbocyclic or heterocyclic ring optionally and independently substituted with 1, 2, or 3 groups selected from alkyl, aryl, heteroaryl, alkoxy, halo, CF_3, OCF_3, or SO_2CH_3 at the substitutable carbon atoms, wherein the 8-10 membered partially saturated bicyclic aryl group having a phenyl ring fused to a non-aromatic carbocyclic or heterocyclic ring is selected from dihydroindenyl, tetrahydronaphthyl, or dihydrobenzodioxinyl.

7. The compound of Claim 1, wherein R^4 is $C(O)OR^7$ and R^7 is independently H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, or C_3-C_{10} alkynyl, wherein the group represented by R^7 is optionally and independently substituted with 1-4 groups selected from hydroxy, halo, amino, aryl, cycloalkyl, heterocyclyl, alkyl, R^9, or R^{10}.

8. The compound of Claim 7, wherein R^7 is C_1-C_{10}alkyl, optionally substituted with halo, hydroxy, amino, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylamino, or di C_1-C_6 alkylamino.

9. The compound of Claim 8, wherein R^1 is H, F, Cl, Br, CF_3, or CH_3.

10. The compound of Claim 8, wherein R^3 is selected from H, cyclopropyl, isopropyl, furanyl, methyl, CF_3, or phenyl.

11. The compound of Claim 1, wherein R^4 is $C(O)NHR^7$ and R^7 is H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12} cycloalkenyl, aryl, haloalkyl, heteroaryl or heterocyclyl, wherein the C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12} cycloalkenyl, aryl, haloalkyl, heteroaryl or heterocyclyl is optionally and independently substituted with 1-4 groups selected from, halo, amino, aryl, cycloalkyl, heterocyclyl, alkyl, R^9, or R^{10}.

12. The compound of Claim 11, wherein R^7 is an aryl, wherein the aryl is phenyl optionally and independently substituted with 1, 2, or 3 groups selected from methyl, methoxy, CF_3, or SO_2CH_3.

13. The compound of Claim 11, wherein R^7 is C_1-C_{10} alkyl, wherein the C_1-C_{10} alkyl is optionally substituted with 1-3 groups selected from amino, halo, hydroxy, phenyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylamino, or diC_1-C_6 alkylamino.

14. The compound of Claim 11, wherein R^1 is H, F, Cl, Br, CF_3,or CH_3.

15. The compound of Claim 11, wherein R^3 is selected from H, methyl, cyclopropyl, isopropyl, furanyl, CF_3, or phenyl.

16. The compound of Claim 1, wherein R^4 is $C(O)NR^{11}R^{12}$ and R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form:

i) a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered saturated or partially saturated ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

ii) a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

iii) a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered ring saturated or partially saturated bicyclic ring having no heteroatom is optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms; or

iv) a 9-10 membered saturated or partially saturated bicyclic ring having 1-5 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfoxide, sulfone, carboxamide or sulfoxamide.

17. The compound of Claim 16, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

18. The compound of Claim 17, wherein said 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded is a 4-6 membered ring, wherein the 4-6 membered ring is azetidinyl, pyrrolidynyl, or piperidynyl optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

19. The compound of Claim 18, wherein said R^5 or R^{5a} is hydroxy, CH_2OH, CH_2CH_2OH, NH_2, NHR^7, $NHCOR^7$, $NHC(O)NHR^7$, or NR^7R^7.

20. The compound of Claim 19, wherein R^1 is H, F, Cl, Br, CF_3, or CH_3.

21. The compound of Claim 19, wherein R^3 is selected from H, methyl, cyclopropyl, isopropyl, furanyl, CF_3, or phenyl.

22. The compound of Claim 1, wherein R^4 is $(CH_2)_nNR^7R^7$, and R^7 is independently H, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{12} cycloalkenyl, aryl, haloalkyl, heteroaryl, or heterocyclyl, wherein the C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{12}cycloalkenyl, aryl, haloalkyl, heteroaryl, or heterocyclyl is optionally and independently substituted with 1-4 groups selected from hydroxyl, halo, amino, aryl, cycloalkyl, heterocyclyl, or alkyl.

23. The compound of Claim 22, wherein R^7 is independently H or C_1-C_{10}alkyl.

24. The compound of Claim 23, wherein R^7 is C_1-C_{10}alkyl optionally substituted with phenyl.

25. The compound of Claim 24, wherein R^1 is H, F, Cl, Br, CF_3, or CH_3.

26. The compound of Claim 25, wherein R^3 is selected from H, methyl, cyclopropyl, isopropyl, furanyl, CF_3, or phenyl.

27. The compound of Claim 1, wherein R^4 is $(CH_2)_nNR^{11}R^{12}$, and R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form:

i) a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered saturated or partially saturated ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

ii) a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

iii) a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom is

optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

iv) a 9-10 membered saturated or partially saturated bicyclic ring having 1-5 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfoxide, sulfone, carboxamide or sulfoxamide; or

v) a 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a}.

28. The compound of Claim 27, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

29. The compound of Claim 28, wherein the 3-8 membered saturated or partially saturated ring is a 4-6 membered ring selected from azetidinyl, pyrrolidinyl, or piperidinyl optionally and independently substituted with 1-2 groups selected from hydroxy, halo, $OC(O)R^7$, CH_2OH, CH_2CH_2OH, NH_2, NR^7R^7, $NHC(O)NHR^7$, $NHSO_2R^7$, $C(O)OR^7$, or $C(O)NHR^7$ at one or more substitutable carbon atoms.

30. The compound of Claim 27, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a}.

31. The compound of Claim 30, wherein the 5-8 membered ring is morpholino, thiomorpholino, piperazinyl or homopiperazinyl, wherein piperazinyl or homopiperazinyl is optionally and independently substituted with hydroxy, C_1-C_{10} alkyl , CH_2CH_2OH, $C(O)R^7$, $C(O)NHR^7$, SO_2R^7, SO_2NHR^7 or $C(O)OR^7$ at the nitrogen atom.

32. The compound of Claim 27, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered saturated or partially saturated bicyclic ring is optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

33. The compound of Claim 32, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form tetrahydroisoquinoline.

34. The compound of Claim 33, wherein R^1 is H, F, Cl, Br, CF_3 or CH_3.

35. The compound of Claim 33, wherein R^3 is selected from H, methyl, cyclopropyl, isopropyl, furanyl, CF_3, or phenyl.

36. The compound of Claim 27, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a}.

37. The compound of Claim 36, wherein the 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, is 2,5-diazabicyclo[2.2.1]heptanyl optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

38. The compound of Claim 36, wherein R^1 is H, F, Cl, Br, CF_3 or CH_3.

39. The compound of Claim 37, wherein R^3 is selected from H, methyl, cyclopropyl, isopropyl, furanyl, CF_3, or phenyl.

40. A compound selected from:

methyl 1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrole-3-carboxylate;

ethyl 1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazole-4-carboxylate;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazole-4-carboxylic acid;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoro pyrimidin-4-yl)-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethyl phenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(2,3-dihydro-*1H*-inden-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethyl-4-phenoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

2-(4-(5-fluoro-4-(3-(hydroxymethyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-fluoro-2-(naphthalene-2-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(4-cyclopropyl-1-(5- methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

2-(4-(4-(3-(hydroxyl methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2,6-dimethoxyphenoxy)ethanol;

2-(4-(4-(4-(3-(hydroxylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2-methylphenyl)piperazin-1-yl)ethanol;

(*S*)-1-(4-(4-(3-(hydroxylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2-methylphenyl)pyrrolidin-3-ol;

(1-(5-fluoro-2-(4-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-(trifluoromethyl)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-phenyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-(furan-3-yl)-*1H*-pyrrol-3-yl)methanol;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*N*-(2-hydroxyethyl)-N,3-dimethyl-*1H*-pyrazole-4-carboxamide;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*N,N*-bis(2-hydroxyethyl)-3-methyl-*1H*-pyrazole-4-carboxamide;

(*S*)-(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

(*R*)-(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

N-(2-aminoethyl)-1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-(trifluoromethyl)-*1H*-pyrazole-4-carboxamide;

1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*N*-(3,5-dimethyl phenyl)-*1H*-pyrazole-4-carboxamide;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazol-4-yl)(piperidin-1-yl)methanone;

(*S*)-1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*N*-(1-hydroxy propan-2-yl)-3-methyl-*1H*-pyrazole-4-carboxamide;

N-benzyl-1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazole-4-carboxamide;

(*R*)-(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methylamino)ethanol;

2-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((4-cyclopropyl-1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(4-((benzylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)pyrimidin-2-amine;

4-(4-(3-((3-hydroxyazetidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenyl methanesulfonate;

(*R*)-4-(4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-*N*,2-dimethylbenzenesulfonamide;

(*R*)-1-((1-(2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl amino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidine-3-carboxylic acid;

(*R*)-1-((1-(2-(3,5-dimethyl-4-phenoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

(*R*)-1-(1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-yl)urea;

1-((4-methyl-1-(2-(2-methylbiphenyl-4-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(2-(2,3-dihydro-*1H*-inden-5-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol1-((4-methyl-1-(2-(1-methyl-*1H*-indol-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-1-((4-methyl-1-(2-(1-methyl-*1H*-indol-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

4-(3-((4,4-difluoropiperidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)pyrimidin-2-amine;

(*R*)-2-(4-(4-(4-((3-hydroxypyrrolidin-1-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

2-(4-(4-(4-((3-hydroxyazetidin-1-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(pyrrolidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(pyrrolidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

(*S*)-2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl amino)propan-1-ol;

4-(4-((cyclopropylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

4-(4-((cyclohexylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(piperidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(morpholinomethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((phenylamino)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

4-(4-((3,4-dihydroisoquinolin-2(*1H*)-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethyl phenyl)-5-fluoropyrimidin-2-amine;

4-(4-((benzyl(methyl)amino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoro pyrimidin-2-amine;

N^1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)ethane-1,2-diamine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(4-((4-fluorophenethylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((pyridin-4-ylmethylamino)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)piperidin-4-ol;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(piperidin-1-ylmethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

1-((3-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrazol-4-yl)methyl)azetidin-3-ol;

2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl amino)ethanol;

4-(4-((benzylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((4-methylpiperazin-1-yl)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

4-(4-((dimethylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((piperidin-4-ylamino) methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine trihydrochloride;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-(3-sulfonylpyrrolidin-1-ylmethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(morpholinomethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

1-((1-(2-(3,4-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-2-(4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

3-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)-3-oxopropanenitrile;

(*R*)-4-(3-((3-aminopyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

1-((1-(5-fluoro-2-(naphthalen-2-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(2-(4-(benzyloxy)-3,5-dimethoxyphenylamino)-5-methylpyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenyl methanesulfonate;

(*R*)-1-((1-(5-fluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-yl acetate;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-yl pivalate;

1-((4-cyclopropyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)urea;

4-(3-((1,4-diazepan-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine trihydrochloride;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

2,2-dimethyl-1-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)-1,4-diazepan-1-yl)propan-1-one;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

(*S*)-2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methylamino)propan-1-ol;

4-(3-((benzylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethoxyphenyl)-5-fluoro pyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-((dimethylamino)methyl)-4-(furan-3-yl)-*1H*-pyrrol-1-yl)-5-fluoro-*N*-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine;

1-((1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) piperidin-4-ol;

N-(3,5-dimethoxyphenyl)-4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(5-fluoro-2-(3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(5-fluoro-2-(3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl) methyl)piperidin-4-ol;

2-(4-((1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

1-((1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-methylpyrimidin-2-amine;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-methylpyrimidin-2-amine;

1-((1-(2-(3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

2-(4-((1-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

4-((1-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)-*N*-methyl-1,4-diazepane-1-carboxamide;

4-((1-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)-1,4-diazepane-1-carboxamide;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

(1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperidin-4-yl)methanol;

1-((1-(2-(3,5-dimethyl-4-(2(pyrrolidin-1-yl)ethoxy)phenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) azetidin-3-ol;

2-(4-(4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methylpyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol;

(*R*)-1-((1-(5-fluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoro-*N*-(3-(trifluoromethyl)phenyl) pyrimidin-2-amine;

2-(4-(5-fluoro-4-(3-((3-hydroxyazetidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-(pyrrolidin-1-yl)ethanone;

(*R*)-1-((1-(2-(3,5-dimethylphenyl amino)-5-(trifluoromethyl) pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-(furan-3-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(3-((dimethylamino)methyl)-4-phenyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-phenyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

N-(3,5-bis(trifluoromethyl)phenyl)-4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

4-(3-((dimethylamino)methyl)-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-(2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-bromo-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine trihydrochloride;

(*R*)-2-(4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

2-(4-(4-(3-(2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methylpyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol trihydrochloride;

4-(3-((1,4-diazepan-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrimidin-2-amine;

1-((1-(5-chloro-2-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol; or

(*R*)-1-((1-(2-(4,6-dimethylpyrimidin-2-ylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol.

41. A isomeric compound of Claim 1.

42. A pharmaceutical formulation comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

43. A method of treating a protein kinase-mediated disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein said protein kinase-mediated disease is selected from the group of consisting of asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohn's disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, bullous disorders, collagenoses, contact dermatitis eczema, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, rheumatoid arthritis, multiple sclerosis, inflammatory bowel syndrome, HIV associated diseases, lupus, lymphoma, osteosarcoma, melanoma, breast cancer, renal cancer, prostate cancer, colorectal cancer, thyroid cancer, ovarian cancer, pancreatic cancer, neuronal cancer, lung cancer, uterine cancer, gastrointestinal cancer, Alzheimer's disease, Parkinson's disease, osteoporosis, osteopenia, osteomalacia, osteofibrosis, Paget's disease, diabetes, blood vessel proliferative disorders, ocular diseases, cardiovascular disease, restenosis, fibrosis, atherosclerosis, arrhythmia, angina, myocardial ischemia, myocardial infarction, cardiac or vascular aneurysm, vasculitis, stroke, peripheral obstructive arteriopathy, reperfusion injury following ischemia of an organ or a tissue, endotoxic, surgical or traumatic shock, hypertension, valvular heart disease, heart failure, abnormal blood pressure, vasoconstriction, vascular abnormality, transplant rejection and infectious diseases including viral and fungal infections.

44. The method of Claim 43, wherein said compound of Claim 1 is administered singly or in combination with one or more additional therapeutic agents.

45. The method of Claim 43, wherein said compound of Claim 1 is administered via intravenous administration, subcutaneous administration, inhalation, oral administration, rectal administration, parenteral, intravitreal administration, intramuscular administration, intranasal administration, dermal administration, topical administration, otic administration, ophthalmic administration, buccal administration, tracheal administration, bronchial administration, or sublingual administration.


46. A method of inhibiting SYK, PYK2, FAK, ZAP70, PIM1, FLT3, RET, JAK2, JAK3, LRRK2, LRRK2(G2019S), ABL1(T315I), AURKB, AXL, FLT3, KIT, KIT(D816V), KIT(V559D,T670I), MKNK2, MLK1, PDGFRB, PLK3, RET, SNARK, SRPK3, TAK1, or TYK2 signaling in a subject in need thereof, comprising administering to said subject an effective amount of a compound of Claim 1.

47. A method of inhibiting growth of cancer cells, comprising contacting the cancer cells with a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

48. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

CLAIMS

1. A compound of Formula (I):



Formula I

wherein:

X is CH or N;

R^1 is selected from H, halo, CN, C_1-C_{10} alkyl or halo(C_1-C_4)alkyl, wherein C_1-C_{10} alkyl, or halo(C_1-C_4)alkyl is optionally substituted;

R^2 is aryl, cycloalkyl, arylalkyl, or heterocyclyl, wherein the aryl, cycloalkyl, arylalkyl, or heterocyclyl is optionally and independently substituted at one or more carbon atoms with 1-4 R^5 or R^{5a} groups; and wherein aryl and heterocyclyl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with 1-4 R^6 or R^{6a} groups;

R^3 is independently halo, CN, or R^7; and

R^4 is selected from $(CH_2)_nOH$, $(CH_2)_nNR^{11}R^{12}$, $C(O)NHR^7$, $C(O)NR^{11}R^{12}$, $C(O)R^7$, $C(O)NR^7R^7$, $C(O)NR^7R^8$, $(CH_2)_nNR^7R^7$, $(CH_2)_nNR^7R^8$, $(CH_2)_nCN$, $(CH_2)_nSR^7$, $(CH_2)_nS(O)_nR^7$, or $(CH_2)_nS(O)_nNR^7R^7$, wherein each n is independently 1 or 2;

wherein:

Each R^5 is independently selected from halo, CF_3, SR^7, OR^7, $OC(O)R^7$, $O(CH_2)_nNR^7R^7$, $O(CH_2)_nNR^{11}R^{12}$, $O(CH_2)_nR^7$, $O(CH_2)_nC(O)NR^{11}R^{12}$, $O(CH_2)_nC(O)NR^7R^7$, NR^7R^7, NR^7R^8, $NHC(O)NH_2$, $C(O)OR^7$, NO_2, CN, $C(O)R^7$, OSO_2CH_3, $S(O)_nR^7$, $S(O)_nNR^7R^7$, $NR^7C(O)NR^7R^7$, $NR^7C(O)R^7$, $NR^7C(O)OR^7$, $NR^7S(O)_nR^7$, or $NR^{11}R^{12}$, wherein each n is independently 1 or 2;

Each R^{5a} is independently selected from amino, halo, hydroxy, C_1-C_{10} alkyl, C_2-C_{10}alkenyl, C_3-C_{10} alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{10}cycloalkenyl, alkoxy, haloalkyl, aryl, heteroaryl, or heterocyclyl, wherein the C_1-C_{10} alkyl, C_2-C_{10}alkenyl, C_3-C_{10} alkynyl, C_3-C_{12}cycloalkyl, C_5-C_{10}cycloalkenyl, alkoxy, haloalkyl, aryl, heteroaryl, or heterocyclyl is optionally and independently substituted with 1 to 3 groups selected from halo, hydroxy, alkyl, R^9, or R^{10};

Each R^6 is independently R^7, $C(O)CH_2CN$, $C(O)R^7$, $C(O)OR^7$, $CO_2(C_1$-C_6alkyl), $C(O)NR^7R^7$, $SO_2NR^7R^7$,or SO_2R^7;

Each R^{6a} is independently hydroxy, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{10} cycloalkenyl, haloalkyl, wherein each R^{6a} group is optionally and independently substituted with 1-3 groups selected from hydroxy, aryl, alkyl, halo, R^9, or R^{10};

Each R^7 is independently H, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12}cycloalkenyl, aryl, aryl(C_1-C_4)alkyl, haloalkyl, heteroaryl, or heterocyclyl, wherein the C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_{10}alkynyl, C_3-C_{12} cycloalkyl, C_5-C_{12}cycloalkenyl, aryl, aryl(C_1-C_4)alkyl, haloalkyl, heteroaryl, or heterocyclyl is optionally and independently substituted with 1-4 groups selected from aryl, cycloalkyl, heteroaryl, heterocyclyl, alkyl, halo, amino, hydroxy, R^9, or R^{10};

Each R^8 is independently $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^7$, or $S(O)_nR^7$, wherein n is 1 or 2;

Each R^9 is independently CF_3, SR^7, OR^7, NR^7R^7, $NR^{11}R^{12}$, $C(O)NR^7R^7$, $C(O)NR^{11}R^{12}$, $S(O)_nNR^7R^7$, or $S(O)_nR^7$, wherein each n is independently 1 or 2;

Each R^{10} is $C(O)O(C_1\text{-}C_6)$alkyl, or halo$(C_1\text{-}C_4)$alkyl; and

R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form:

i) a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered saturated or partially saturated ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

ii) a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

iii) a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom is optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

iv) a 9-10 membered saturated or partially saturated bicyclic ring having 1-5 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded,

wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfoxide, sulfone, carboxamide or sulfoxamide; or

v) a 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1, wherein R^2 is an aryl selected from: a 5-6 membered monocyclic aryl group having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-10 membered bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone; an 8-10 membered partially saturated bicyclic aryl group having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, sulfoxide, or sulfone; or an 8-10 membered partially saturated bicyclic aryl group having a carboxamide or sulfoxamide.

3. The compound of Claim 2, wherein R^2 is a 5-6 membered monocyclic aryl having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur optionally and independently substituted with 1-4 R^5 or R^{5a} groups.

4. The compound of Claim 3, wherein the 5-6 membered monocyclic aryl is phenyl or pyrimidinyl optionally and independently substituted with 1, 2, or 3 groups selected from methyl, ethyl, phenyl, isoprophyl, methoxy, hydroxyethoxy, CF_3, OC_6H_5,

$OCH_2CH_2NR^{11}R^{12}$, $OCH_2CH_2NR^7R^7$, $OCH_2C_6H_5$, $OCH_2C(O)NR^{11}R^{12}$, $OCH_2C(O)NR^7R^7$, OSO_2CH_3, SO_2CH_3, SO_2NHCH_3, or $NR^{11}R^{12}$.

5. The compound of Claim 1, wherein R^4 is $(CH_2)_nNR^{11}R^{12}$, and R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form:

i) a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered saturated or partially saturated ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

ii) a 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, and wherein said 5-8 membered saturated or partially saturated ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a};

iii) a 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 9-10 membered saturated or partially saturated bicyclic ring having no heteroatom is optionally substituted with 1-4 groups independently selected from R^5 or R^{5a} at one or more substitutable carbon atoms;

iv) a 9-10 membered saturated or partially saturated bicyclic ring having 1-5 heteroatoms, in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfoxide, sulfone, carboxamide or sulfoxamide; or

v) a 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms in addition to the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 1-3 heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone, or sulfoxide, and wherein said 6-14 membered saturated or partially saturated bridged ring having 1-3 heteroatoms is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms and at one or more substitutable nitrogen atoms with R^6 or R^{6a}.

6. The compound of Claim 5, wherein R^{11} and R^{12}, taken together with the nitrogen atom to which they are bonded form a 3-8 membered saturated or partially saturated ring having no heteroatom other than the nitrogen atom to which R^{11} and R^{12} are bonded, wherein said 3-8 membered ring is optionally and independently substituted with 1-4 groups selected from R^5 or R^{5a} at one or more substitutable carbon atoms.

7. The compound of Claim 6, wherein the 3-8 membered saturated or partially saturated ring is a 4-6 membered ring selected from azetidinyl, pyrrolidinyl, or piperidinyl optionally and independently substituted with 1-2 groups selected from hydroxy, halo, $OC(O)R^7$, CH_2OH, CH_2CH_2OH, NH_2, NR^7R^7, $NHC(O)NHR^7$, $NHSO_2R^7$, $C(O)OR^7$, or $C(O)NHR^7$ at one or more substitutable carbon atoms.

8. A compound selected from:

methyl 1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrole-3-carboxylate;

ethyl 1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazole-4-carboxylate;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazole-4-carboxylic acid;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoro pyrimidin-4-yl)-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methanol;

(1-(2-(3,5-dimethyl phenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(2,3-dihydro-*1H*-inden-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethyl-4-phenoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

2-(4-(5-fluoro-4-(3-(hydroxymethyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-fluoro-2-(naphthalene-2-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(4-cyclopropyl-1-(5- methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

(4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methanol;

2-(4-(4-(3-(hydroxyl methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2,6-dimethoxyphenoxy)ethanol;

2-(4-(4-(4-(3-(hydroxylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2-methylphenyl)piperazin-1-yl)ethanol;

(*S*)-1-(4-(4-(3-(hydroxylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl pyrimidin-2-ylamino)-2-methylphenyl)pyrrolidin-3-ol;

(1-(5-fluoro-2-(4-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-(trifluoromethyl)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methanol;

(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-phenyl-*1H*-pyrrol-3-yl)methanol;

(1-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-(furan-3-yl)-*1H*-pyrrol-3-yl)methanol;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*N*-(2-hydroxyethyl)-N,3-dimethyl-*1H*-pyrazole-4-carboxamide;

1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*N,N*-bis(2-hydroxyethyl)-3-methyl-*1H*-pyrazole-4-carboxamide;

(*S*)-(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

(*R*)-(1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

N-(2-aminoethyl)-1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-3-(trifluoromethyl)-*1H*-pyrazole-4-carboxamide;

1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*N*-(3,5-dimethyl phenyl)-*1H*-pyrazole-4-carboxamide;

(1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazol-4-yl)(piperidin-1-yl)methanone;

(*S*)-1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*N*-(1-hydroxy propan-2-yl)-3-methyl-*1H*-pyrazole-4-carboxamide;

N-benzyl-1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrazole-4-carboxamide;

(*R*)-(1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)(3-hydroxypyrrolidin-1-yl)methanone;

2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methylamino)ethanol;

2-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((4-cyclopropyl-1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(4-((benzylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)pyrimidin-2-amine;

4-(4-(3-((3-hydroxyazetidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenyl methanesulfonate;

(*R*)-4-(4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-*N*,2-dimethylbenzenesulfonamide;

(*R*)-1-((1-(2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl amino)pyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidine-3-carboxylic acid;

(*R*)-1-((1-(2-(3,5-dimethyl-4-phenoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

(*R*)-1-(1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-yl)urea;

1-((4-methyl-1-(2-(2-methylbiphenyl-4-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(2-(2,3-dihydro-*1H*-inden-5-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol1-((4-methyl-1-(2-(1-methyl-*1H*-indol-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-1-((4-methyl-1-(2-(1-methyl-*1H*-indol-5-ylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

4-(3-((4,4-difluoropiperidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)pyrimidin-2-amine;

(*R*)-2-(4-(4-(4-((3-hydroxypyrrolidin-1-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

2-(4-(4-(4-((3-hydroxyazetidin-1-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(pyrrolidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(pyrrolidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

(*S*)-2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl amino)propan-1-ol;

4-(4-((cyclopropylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

4-(4-((cyclohexylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(piperidin-1-ylmethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(morpholinomethyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((phenylamino)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

4-(4-((3,4-dihydroisoquinolin-2(*1H*)-yl)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethyl phenyl)-5-fluoropyrimidin-2-amine;

4-(4-((benzyl(methyl)amino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoro pyrimidin-2-amine;

N^1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)ethane-1,2-diamine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(4-((4-fluorophenethylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((pyridin-4-ylmethylamino)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl)piperidin-4-ol;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(piperidin-1-ylmethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

1-((3-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrazol-4-yl)methyl)azetidin-3-ol;

2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-3-methyl-*1H*-pyrazol-4-yl)methyl amino)ethanol;

4-(4-((benzylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((4-methylpiperazin-1-yl)methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine;

4-(4-((dimethylamino)methyl)-3-methyl-*1H*-pyrazol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-((piperidin-4-ylamino) methyl)-*1H*-pyrazol-1-yl)pyrimidin-2-amine trihydrochloride;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-(3-sulfonylpyrrolidin-1-ylmethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

N-(3,5-dimethylphenyl)-5-fluoro-4-(3-methyl-4-(morpholinomethyl)-*1H*-pyrrol-1-yl)pyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

1-((1-(2-(3,4-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-2-(4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

3-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)-3-oxopropanenitrile;

(*R*)-4-(3-((3-aminopyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

1-((1-(5-fluoro-2-(naphthalen-2-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(2-(4-(benzyloxy)-3,5-dimethoxyphenylamino)-5-methylpyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

(*R*)-4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenyl methanesulfonate;

(*R*)-1-((1-(5-fluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-yl acetate;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-yl pivalate;

1-((4-cyclopropyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)urea;

4-(3-((1,4-diazepan-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methyl-*N*-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine trihydrochloride;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) pyrrolidin-3-ol;

2,2-dimethyl-1-(4-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)-1,4-diazepan-1-yl)propan-1-one;

(*S*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

(*S*)-2-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methylamino)propan-1-ol;

4-(3-((benzylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethoxyphenyl)-5-fluoro pyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-((dimethylamino)methyl)-4-(furan-3-yl)-*1H*-pyrrol-1-yl)-5-fluoro-*N*-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine;

1-((1-(2-(3,5-dimethoxyphenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) piperidin-4-ol;

N-(3,5-dimethoxyphenyl)-4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(5-fluoro-2-(3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(5-fluoro-2-(3-(trifluoromethyl)phenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl) methyl)piperidin-4-ol;

2-(4-((1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

1-((1-(5-chloro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

1-((1-(5-chloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-methylpyrimidin-2-amine;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-methylpyrimidin-2-amine;

1-((1-(2-(3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

2-(4-((1-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperazin-1-yl)ethanol;

4-((1-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)-*N*-methyl-1,4-diazepane-1-carboxamide;

4-((1-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)-1,4-diazepane-1-carboxamide;

1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

(1-((4-methyl-1-(5-methyl-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)piperidin-4-yl)methanol;

1-((1-(2-(3,5-dimethyl-4-(2(pyrrolidin-1-yl)ethoxy)phenylamino)-5-methylpyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl) azetidin-3-ol;

2-(4-(4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methylpyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol;

(*R*)-1-((1-(5-fluoro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoro-*N*-(3-(trifluoromethyl)phenyl) pyrimidin-2-amine;

2-(4-(5-fluoro-4-(3-((3-hydroxyazetidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-(pyrrolidin-1-yl)ethanone;

(*R*)-1-((1-(2-(3,5-dimethylphenyl amino)-5-(trifluoromethyl) pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)-4-(furan-3-yl)-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol;

4-(3-((dimethylamino)methyl)-4-phenyl-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-4-phenyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

N-(3,5-bis(trifluoromethyl)phenyl)-4-(3-((dimethylamino)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

1-((1-(2-(3,5-bis(trifluoromethyl)phenylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)piperidin-4-ol;

4-(3-((dimethylamino)methyl)-*1H*-pyrrol-1-yl)-*N*-(3,5-dimethylphenyl)-5-fluoropyrimidin-2-amine;

(*R*)-1-((1-(2-(3,5-dimethylphenylamino)-5-fluoropyrimidin-4-yl)-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol;

4-(3-(2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-bromo-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine trihydrochloride;

(*R*)-2-(4-(5-fluoro-4-(3-((3-hydroxypyrrolidin-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)pyrimidin-2-ylamino)-2,6-dimethylphenoxy)-1-morpholinoethanone;

2-(4-(4-(3-(2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)-4-methyl-*1H*-pyrrol-1-yl)-5-methylpyrimidin-2-ylamino)-2,6-dimethylphenoxy)ethanol trihydrochloride;

4-(3-((1,4-diazepan-1-yl)methyl)-4-methyl-*1H*-pyrrol-1-yl)-5-chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrimidin-2-amine;

1-((1-(5-chloro-2-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylamino)pyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)azetidin-3-ol; or

(*R*)-1-((1-(2-(4,6-dimethylpyrimidin-2-ylamino)-5-fluoropyrimidin-4-yl)-4-methyl-*1H*-pyrrol-3-yl)methyl)pyrrolidin-3-ol.

9. A pharmaceutical formulation comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

10. The compound of claim 1, wherein X is CH.